The Institute for Clinical and Economic Review (ICER) is targeting unjustified price increases (UPIs) as it looks to expand its focus beyond quality-adjust life year (QALY) analysis, Pharmaceutical Executive reports. The nonprofit recently released a draft protocol for a new annual report that will […]
Report: ICER’s International Push Signals Dedication to Improved HTA
The Institute for Clinical and Economic Review's (ICER) recently-announced global initiative to create new and improved value-based pricing strategies is a "clear signal of the internationalization and desire for harmonization of HTA," according to a recent article published on Pharmaceutical […]
ICER Announces International Partnership to Develop New Assessment Methods
The Institute for Clinical and Economic Review (ICER) on Wednesday, Jan. 23, announced a global initiative aimed at creating new, alternative methods for evaluating innovative therapies and recommending value-based pricing benchmarks. According to a press release, the organization will work with a […]
ICER Plans New Annual Report on Price Increases
The Institute for Clinical and Economic Review (ICER) this week released a report outlining a new annual review which will look to determine whether significant price increases on prescription drugs are supported by clinical evidence. The "Unsupported Price Increase" report remains in the planning […]
ICER Outlines Planned Review of DMD Treatments
The Institute for Clinical and Economic Review on Friday released a report outlining a planned review of Duchenne muscular dystrophy treatments. ICER plans to review Sarepta Therapeutics' eteplirsen and golodirsen, and PTC Therapeutics' deflazacort. While the Food and Drug Administration has […]
- Previous Page
- 1
- …
- 13
- 14
- 15
